Mental health screening used to rely heavily on lengthy clinical interviews, making it difficult to catch depression early in a standard 15-minute primary care visit.
Today, a simple nine-question form has become the standard for identifying and measuring depression severity across medical disciplines.
That form is the PHQ-9.
If your practice is updating its intake protocols or moving to digital assessments, understanding exactly how this tool works is your first step.
What is the PHQ-9?
The Patient Health Questionnaire-9 (PHQ-9) is a brief, self-administered screening tool designed to detect and measure the severity of depression. It was developed in the late 1990s by Drs. Robert L. Spitzer, Janet B.W. Williams, and Kurt Kroenke. They extracted the nine depression criteria directly from the Diagnostic and Statistical Manual of Mental Disorders (DSM-IV) and turned them into a patient-facing survey.
The result is a highly validated instrument that takes patients less than three minutes to complete. It acts as both an initial screen to flag potential depressive disorders and a reliable metric to track a patient's response to treatment over time. Because it is free to use and heavily backed by clinical research, it has been adopted globally in both primary care and specialized psychiatric settings.
The nine items of the Patient Health Questionnaire-9
The questionnaire asks patients how often they have been bothered by specific problems over the last two weeks. Each item targets a core symptom of major depressive disorder:
- Anhedonia: Little interest or pleasure in doing things.
- Depressed mood: Feeling down, depressed, or hopeless.
- Sleep disturbances: Trouble falling or staying asleep, or sleeping too much.
- Energy levels: Feeling tired or having little energy.
- Appetite changes: Poor appetite or overeating.
- Self-esteem: Feeling bad about yourself, or feeling that you are a failure or have let yourself or your family down.
- Concentration: Trouble concentrating on things, such as reading the newspaper or watching television.
- Psychomotor changes: Moving or speaking so slowly that other people could have noticed, or the opposite - being so fidgety or restless that you have been moving around a lot more than usual.
- Suicidal ideation: Thoughts that you would be better off dead, or of hurting yourself in some way.
Understanding PHQ-9 scoring ranges
Patients rate each of the nine items on a frequency scale from 0 to 3. The options are Not at all (0), Several days (1), More than half the days (2), and Nearly every day (3).
The total score caps at 27. Clinicians use these score brackets to guide their next steps, a process essential to modern mental health assessment workflows.
| Total score | Depression severity | Clinical action |
|---|---|---|
| 0-4 | None-minimal | None |
| 5-9 | Mild | Watchful waiting; repeat at follow-up |
| 10-14 | Moderate | Consider counseling, follow-up, or pharmacotherapy |
| 15-19 | Moderately severe | Active treatment with pharmacotherapy and/or psychotherapy |
| 20-27 | Severe | Immediate active treatment; consider specialist referral |
A tenth question typically appears at the bottom of the form, asking how difficult these problems have made it for the patient to do work, take care of things at home, or get along with other people. This functional impairment question is not factored into the numerical score, but it provides critical context for the clinician when deciding on a treatment plan.
Clinical applications of the depression screen
The PHQ-9 serves multiple roles depending on the clinical setting and the patient's history.
- Initial screening: Primary care providers use it during annual physicals or standard intake visits to catch silent cases of depression before they escalate.
- Establishing a baseline: When a patient presents with mood complaints, the initial score gives the clinician a quantifiable starting point rather than relying solely on subjective descriptions.
- Treatment monitoring: Psychiatrists and therapists readminister the questionnaire at regular intervals to see if a medication adjustment or therapeutic intervention is working.
- Suicide risk assessment: The ninth question specifically flags self-harm ideation, alerting the provider to step away from routine screening and initiate immediate safety and triage protocols.
How the PHQ-9 differs from the GAD-7
Medical practices frequently administer two screening forms side by side, but they measure entirely different conditions.
The PHQ-9 evaluates depression, focusing heavily on mood, energy, and anhedonia. The Generalized Anxiety Disorder 7-item scale (GAD-7) evaluates anxiety, focusing on worry, restlessness, and irritability.
Because depression and anxiety present together so often, clinicians combine them into a single assessment workflow. If a patient scores high on the PHQ-9 but low on the GAD-7, the treatment plan leans toward depression protocols rather than anti-anxiety interventions. Using both ensures a provider does not misdiagnose a mixed presentation.
Streamlining patient screening in your practice
Handing a patient a clipboard and a paper PHQ-9 creates administrative drag across the healthcare industry. Someone has to manually add up the scores, enter the data into the electronic health record, and physically shred or scan the paper.
Moving to digital assessments allows the form to calculate the score automatically before the provider even steps into the exam room. This shifts the focus from administrative data entry directly to patient care.
Expert tip: If you are migrating a clinic from paper records to digital intake, use a tool to convert your intake form PDFs to Google Forms so you do not have to rebuild complex clinical questionnaires from scratch.
FAQ
Is the PHQ-9 a diagnostic tool for depression?
No, the PHQ-9 is a screening and monitoring tool, not a standalone diagnostic instrument. While a high score strongly suggests the presence of major depressive disorder, a formal diagnosis requires a clinical interview by a qualified healthcare professional. The provider must rule out other causes for the symptoms, such as thyroid issues, medication side effects, or bipolar disorder.
Can patients self-administer the PHQ-9?
Yes, the questionnaire was specifically designed for self-administration. The language is plain and the instructions are simple enough for patients to complete in a waiting room or via a patient portal at home. This saves valuable consultation time for discussing the results and formulating a treatment plan.
How often should the PHQ-9 be administered to track progress?
Most clinical guidelines recommend readministering the assessment every two to four weeks during the active phase of treatment. Once a patient achieves remission or stabilizes, the frequency can be reduced to every few months or during routine follow-up visits. Frequent measurement helps providers quickly identify if a prescribed antidepressant or therapy approach is ineffective.
What is considered a clinically significant change in a PHQ-9 score?
A drop of five points or more from the baseline score is generally considered a clinically significant improvement. Alternatively, a 50 percent reduction in the total score indicates a robust response to treatment. If a score drops below five, the patient is typically considered to be in remission.
Standardizing how you screen for depression removes the guesswork from patient care. By adopting validated tools like the PHQ-9 and moving them into accessible digital formats using platforms like Doc2Form to digitize existing clinical paperwork, you ensure critical mental health data is captured accurately, scored instantly, and ready for discussion the moment the appointment begins.
